Current Challenges in CAR T Manufacturing

The article discusses the challenges in manufacturing CAR T therapies, which have transitioned from experimental treatments to clinically validated therapies with a $6 billion global market. The primary bottleneck in manufacturing is scalability, driven by donor-to-donor variability, patient-specific production, and complex multi-step workflows within tightly controlled GMP environments.

These factors increase costs, create process variability, and limit manufacturing throughput, ultimately restricting patient access to these life-saving therapies. Additionally, existing analytical approaches are limited in real-time prediction of manufacturing outcomes, relying on downstream or metabolite-based measurements that do not provide insights into what a cell can become.

To address these challenges, Cytomos has developed AuraCyt, a predictive cell intelligence platform that uses dielectric spectroscopy to reveal cellular states earlier in the manufacturing process, enabling informed intervention and a transition from reactive to proactive process control.

Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.